logo

For the Inventor, By the Inventor

Wuppertal, Germany

Eike Moller

This inventor holds 32 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Bayer Aktiengesellschaft, Baker Aktiengesellshaft, Wayne State University. Active years: 1976-1988.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eike Moller. Retrieved from https://idiyas.com/inventor/eike-moller

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 32

% Patents Active = 100.0

Average Co-Inventor Count = 4.2

ph-index = 5

Forward Citations = 110(Granted Patents)


Company Filing History:

goldMedal30 out of 12,268 
 
Bayer Aktiengesellschaft
 patents
silverMedal1 out of 1 
 
Baker Aktiengesellshaft
 patent
bronzeMedal1 out of 603 
 
Wayne State University
 patents

Years Active: 1976-1988

Loading Chart...
Areas of Expertise:
Tumor Cell Metastasis
Imidazoazole Compounds
Pyrazole Derivatives
Antithrombotic
Pharmaceutical Compositions
Intermediate Products
4-Substituted Pyrazoles
5-Sulphonyloxy Pyrazoles
Composition
New Compounds
32 patents (USPTO):Explore Patents
1. 4760066 - Method for treating human tumor cell metastasis (1988-07-26),
2. 4444770 - New imidazoazole-alkenoic acid amide compounds, intermediate products (1984-04-24),
3. 4288446 - Pyrazol-5-ones (1981-09-08),
4. 4265898 - Imidazo[2,1-b]-[1,3,4]-thiadiazole compounds, composition and their (1981-05-05),
5. 4207325 - 4-Substituted pyrazoles (1980-06-10),
6. 4160098 - Pyrazole derivatives (1979-07-03),
7. 4122281 - 5-Sulphonyloxy pyrazole derivatives (1978-10-24),
8. 4122280 - Pyrazole derivatives (1978-10-24),
9. 4122279 - Pyrazole derivatives (1978-10-24),
10. 4117145 - 1-Substituted pyrazoles (1978-09-26),
11. 4117143 - 1-Substituted pyrazoles (1978-09-26),
12. 4113957 - 1-Substituted pyrazoles (1978-09-12),
13. 4113872 - 4-Substituted pyrazoles (1978-09-12),
14. 4112227 - Pyrazol-5-ones (1978-09-05),
15. 4112109 - 4-Substituted pyrazoles (1978-09-05),

Title: Eike Moller: Innovator in Cancer Treatment

Introduction

Eike Moller, a prolific inventor based in Wuppertal, Germany, holds an impressive portfolio of 32 patents. His contributions to the field of medical innovations, particularly in cancer treatment, have significantly advanced therapeutic methodologies.

Latest Patents

Among his latest patents, Moller has developed a method for treating human tumor cell metastasis. This therapeutic approach focuses on administering a therapeutically effective amount of 3-methyl-1-[2-(2-naphthyloxy)-ethyl]-2-pyrazolin-5-one or its pharmaceutically acceptable salt. Additionally, he has patented new imidazoazole-alkenoic acid amide compounds, describing their production methods and their applications in medical compositions. This invention also includes carbonyl compounds and alkenoic acids as intermediates, further showcasing his innovative approach to cancer therapies.

Career Highlights

Eike Moller has made significant strides in his career, having worked with renowned organizations such as Bayer Aktiengesellschaft and Wayne State University. His work in these institutions has been instrumental in the advancement of research in pharmaceuticals, particularly in oncology.

Collaborations

Throughout his career, Moller has collaborated with notable professionals in his field, including Harald Horstmann and Egbert Wehinger. His partnerships with such expertise have fostered fruitful innovation and development of groundbreaking therapies.

Conclusion

Eike Moller’s dedication to medical innovation is evident through his extensive patent portfolio and collaborations with distinguished institutions and professionals. His work continues to influence the landscape of cancer treatment, illustrating the impact of innovative thinking and collaboration in the field of pharmaceuticals.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…